<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1428</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10416374</PubmedId>
            <Abstract>Chaperonin 10 of M. tuberculosis conferred partial or total protection against generalized foot-and-mouth disease (FMD) in guinea-pigs challenged with O1 Lausanne FMD virus. Chaperonin 10-immunized animals mounted an antibody response to the protein, one epitope of which was found in the C-terminal half. A similar recognition pattern was observed in FMD-convalescent guinea-pigs, swine and cattle. Anti-chaperonin 10 sera showed antiviral activity against FMDV-infected BHK-21 cells. There was strong evidence that early after infection these cells actively secrete their histones and that antisera to the chaperonin recognize them. The same antisera reacted with purified histones in immunoblotting. Most important, exogenously added histones abrogated the anti-viral activity of the antiserum and an anti-histone monoclonal antibody had strong antiviral activity against FMDV-infected BHK-21 cells. These results are consistent with previous reports on displacement of histones from the nuclear compartment and immune recognition of self-histones after viral infections. On the whole, they indicate that M. tuberculosis chaperonin 10 enables the immune system to react against early abnormalities of virus-infected cells; this is accomplished by antibody cross-reacting with histones released during virus infection.</Abstract>
            <ArticleYear>1999</ArticleYear>
            <ArticlePages>905-19</ArticlePages>
            <ArticleTitle>Chaperonin 10 of Mycobacterium tuberculosis induces a protective immune response to foot-and-mouth disease virus.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Amadori</LastName>
                    <ForeName>M</ForeName>
                </Author>
                <Author>
                    <LastName>Archetti</LastName>
                    <ForeName>I L</ForeName>
                </Author>
                <Author>
                    <LastName>Scaccaglia</LastName>
                    <ForeName>P</ForeName>
                </Author>
                <Author>
                    <LastName>Modena</LastName>
                    <ForeName>D</ForeName>
                </Author>
                <Author>
                    <LastName>Fossati</LastName>
                    <ForeName>G</ForeName>
                </Author>
                <Author>
                    <LastName>Lucietto</LastName>
                    <ForeName>P</ForeName>
                </Author>
                <Author>
                    <LastName>Mascagni</LastName>
                    <ForeName>P</ForeName>
                </Author>
            </Authors>
            <Affiliations>Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia, Department of Vaccine Research and Development, Brescia, Italy.</Affiliations>
            <ArticleChemicalList>Antibodies, Viral;Chaperonin 10;Histones;Peptide Fragments</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Antibodies, Viral(immunology); Antibody Formation; Aphthovirus(immunology; pathogenicity); Cattle; Cell Line; Chaperonin 10(chemistry; immunology; therapeutic use); Cricetinae; Foot-and-Mouth Disease(immunology; prevention &amp; control); Guinea Pigs; Histones(biosynthesis; immunology); Molecular Sequence Data; Mycobacterium tuberculosis(immunology); Peptide Fragments(chemistry; immunology; therapeutic use); Swine</ArticleMeshHeadingsList>
            <Journal>
                <Volume>144</Volume>
                <Issue>5</Issue>
                <Title>Archives of virology</Title>
                <Issn>1432-8798</Issn>
                <MedlineTa>Arch Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>VP1 140-160 peptide</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AVPNLRGDLQVLAQKVARTL</LinearSequence>
                        <StartingPosition>140</StartingPosition>
                        <EndingPosition>159</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAZ31349.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>12110</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Tables 1 and 2</LocationOfData>
                <EpitopeId>5505</EpitopeId>
                <ReferenceStartingPosition>140</ReferenceStartingPosition>
                <ReferenceEndingPosition>159</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Tables 1 and 2</LocationOfData>
                        <BCellId>22182</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10141</OrganismId>
                                <Sex>M</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>AVPNLRGDLQVLAQKVARTL</LinearSequence>
                                            <StartingPosition>140</StartingPosition>
                                            <EndingPosition>159</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>AAZ31349.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>12110</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>VP1 140-160 peptide</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>P02769.4</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>9913</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose(s) of molar equivalent of 50 ug peptide in terms of peptide-BSA conjugate in 1 ml adjuvant</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>In some cases, a booster injection was carried out 30 days after the primary immunization. Also, in order to conjugate the peptide to BSA, a terminal cysteine residue was added to the peptide during synthesis.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>125</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>60</ResponseFrequency>
                            <AssayComments>Immunization with the peptide conjugated to BSA protected against virus challenge, while immunization without BSA did not. There was a trend towards decreasing numbers of vesicular lesions in 4 animals from Day 7 to Day 11 post-infection.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenReferenceName>Foot-and-mouth disease virus</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>12110</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

